Cognition Therapeutics Q2 net loss narrows on lower R&D costs
CGTX•Quarterly results and cash position
Cognition Therapeutics' Q2 net loss narrowed as research and development expenses declined sharply.
The company ended Q2 with $34.8 million in cash and expects to fund operations into Q4 2027.
| Metric | Actual |
|---|---|
| Q2 net loss | $3.93 million |
| Q2 loss from operations | -$7.74 million |
| Q2 operating expenses | $7.74 million |
Spending drivers and pipeline progress
The company said the decrease in research and development expenses was due to reduced trial activities, compensation and professional fees.
General and administrative expenses increased due to higher professional fees.
Cognition Therapeutics also said it made progress on its planned Phase 3 trial for DLB psychosis, and that a new zervimesine patent allowance could extend protection through 2045.
The company did not provide specific financial guidance for the current or future periods.
